Macrophage Engager (ME) based Bispecific Antibody (BsAb) Design Service

BsAbs are emerging as a transformative modality in targeted therapeutics, enabling simultaneous engagement of two distinct antigens. Macrophage Engager (ME) BsAb Design Service in Creative Biolabs leverages this dual-targeting paradigm to pioneer innovative immunotherapies. ME-BsAbs are engineered to harness the phagocytic potential of macrophages, prevalent immune cells within the tumor microenvironment. By disrupting inhibitory "don't-eat-me" signals and amplifying stimulatory "eat-me" cues, these BsAbs redirect macrophage activity towards target cell elimination. This approach offers a compelling strategy for therapeutic intervention, particularly within oncology and other domains requiring precise immune modulation.

Fig.1 Schematic depiction of immunotherapeutic strategies targeting cancer stem cells, featuring BsAbs and antibody–drug candidates.¹

Overview of ME-based BsAb Design Service

ME-Based BsAbs incorporating an Fc region that engages Fcγ receptors enlist accessory immune cells, including dendritic cells, natural killer cells, and macrophages. Upon being redirected to tumor cells, these effector cells secrete cytotoxic, pro-inflammatory cytokines. Ultimately, tumor cell elimination is achieved via mechanisms such as ADCC, phagocytosis, and T cell-mediated lysis. As a predominant subset of immune cells infiltrating the tumor microenvironment (TME), macrophages are pervasive across all tumor types. Recent investigations highlight the promise of directing therapeutic strategies toward tumor-associated macrophages (TAMs) to enhance antigen presentation.

Hot Targets in Our Service

Creative Biolabs has engineered ME-based BsAbs that simultaneously target CD89 and tumor-associated antigens, such as the Recombinant Anti-CD89 x Anti-EGFR Bispecific Antibody (IgG-scFv). Binding to CD89 not only enhances antigen presentation but also promotes phagocytosis, antibody-dependent cellular cytotoxicity (ADCC), and the release of pro-inflammatory mediators. Activation of CD89 signaling correlates with elevated antigen presentation, improved M1/M2 macrophage ratios, and increased lymphocyte infiltration in tumor sites of CD89-transgenic mice, thereby enhancing PD-1 blockade effectiveness. We provide a range of popular BsAb targets along with specialized custom design services for ME-based BsAbs.

Creative Biolabs boasts a highly skilled research team with deep expertise in bispecific antibodies, supported by cutting-edge engineering platforms. Our custom ME-based BsAbs development services encompass every phase—from molecular design and engineering to production and thorough analytical characterization.